熱門資訊> 正文
吉利德加州总部制造开发基地奠基
2025-09-04 00:24
- Gilead Sciences (NASDAQ:GILD) has broken ground on its Pharmaceutical Development and ManufacturingTechnical Development Center (NTDC) at the biotech's Foster City, Calif., headquarters.
- The building is part of the company's planned $32B manufacturing and R&D investments in the U.S. through 2030.
- The 180,000-square-foot structure "will serve as a hub for innovation and collaboration across technical development and manufacturing teams," according to a Gilead news release. "Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead’s pipeline.
- "It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharma industry."
- Gilead is also developing two other buildings in Foster City. One is a research building under construction, while the other is a biologics manufacturing site.
More on Gilead Sciences
- Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales
- From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
- Gilead Sciences' Outperformance Means Overvalued
- Gilead is said to seek price hikes for HIV meds supplied for state AIDS drug programs
- Gilead granted EU nod for twice-yearly HIV PrEP therapy
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。